G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.
Shaheenah Dawood,Xiudong Lei,Jennifer K. Litton,Thomas A. Buchholz,Gabriel N. Hortobagyi,Ana M. Gonzalez-Angulo +5 more
TL;DR: This retrospective study sought to define the incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer (TNBC).
Journal ArticleDOI
Long-term Survival Outcomes of Triple-Receptor Negative Breast Cancer Survivors Who Are Disease Free at 5 Years and Relationship With Low Hormone Receptor Positivity
Sangeetha M. Reddy,Carlos H. Barcenas,Arup Kumar Sinha,Limin Hsu,S. L. Moulder,Debu Tripathy,Gabriel N. Hortobagyi,V. Valero +7 more
TL;DR: The TNBC survivors who have been disease free for 5 years have a low probability of experiencing recurrence over the subsequent 10 years, and patients with low hormone receptor-positive cancers may have a higher risk of late events as measured by RFS but not by RFI or DRFS.
Journal ArticleDOI
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens.
Aman U Buzdar,Sewa S. Legha,Gabriel N. Hortobagyi,Hwee-Yong Yap,Charles L. Wiseman,Alfred Distefano,Frank C. Schell,Brian C. Barnes,Luis T. Campos,George R. Blumenschein +9 more
TL;DR: Survival was significantly longer in asymptomatic patients compared with those who were symptomatic from recurrent disease, and in patients treated with Adriamycin‐containing adjuvant chemotherapy with objective remission with hormonal therapies.